Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN

Completed

• Conditions: Primary IgA Nephropathy
• Interventions: Drug: TARPEYO 4 MG Delayed Release Oral Capsule; Drug: RAS inhibitor

• Registration Number: NCT06589752
• Lead Sponsor: Ruijin Hospital

Brief Summary

This replication of the NefIgArd trial of TRF-budesonide aims to use real-world data to evaluate the efficiency and safety of TRF-budesonide in the treatment of IgA nephropathy, from completing real-world research to providing real-world evidence.

Detailed Description

Currently, TRF-budesonide are the first specific treatment for IgA nephropathy that targets intestinal mucosal immunity. Results from part A of the Phase III clinical trial (NCT03643965) show that compared to the placebo group, the TRF-budesonide group significantly reduced proteinuria and hematuria, stabilized renal function, and lowered circulating Gd-IgA1 levels at 12 months. However, further real-world studies are needed to verify the efficiency and safety of this treatment for IgA nephropathy. Therefore, this replication trial of the part A of the Phase III clinical trial NefIgArd and evaluates the efficiency and safety of TRF-budesonide in treating IgA nephropathy based on existing observational data, aiming to complete real-world research to provide real-world evidence that can guide clinical practice for IgA nephropathy treatment.

Study Timeline

• Study Start: 2023-04-24
• Study First Submitted: 2024-07-21
• Status Verified: 2024-09
• Primary Completion: 2024-09-05
• Study Completion: 2024-09-05
• Study First Submitted QC: 2024-09-05
• Last Update Submitted: 2024-09-05
• Study First Posted: 2024-09-10
• Last Update Posted: 2024-09-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Male or female patients aged ≥18 years;
2. Primary IgA nephropathy confirmed by renal biopsy;
3. Stable use of RAS blockers;
4. 24-hour urine albumin quantitation ≥1g/day, or urine protein/creatinine ratio ≥0.8g/g (≥90 mg/mmol);
5. eGFR ≥30 mL/min/1.73m².

Exclusion Criteria

1. Systemic diseases that may cause interstitial IgA deposition, including but not limited to anaphylactoid purpura, systemic lupus erythematosus, herpetic dermatitis, and ankylosing spondylitis;
2. Patients who have received kidney transplants;
3. Those with other glomerular diseases (such as C3 glomerular disease or diabetic nephropathy) and nephrotic syndrome;
4. Patients with acute, chronic, or latent infectious diseases, including hepatitis, tuberculosis (TB), human immunodeficiency virus (HIV), and chronic urinary tract infections;
5. Patients with cirrhosis or severe liver function impairment, as assessed by the investigator;
6. Patients diagnosed with poorly controlled type 1 or type 2 diabetes;
7. Patients with a history of unstable angina, grade III or IV congestive heart failure, and/or arrhythmia as assessed by the investigator;
8. Patients with poorly controlled blood pressure with systolic or diastolic blood pressure ≥140mmHg or 90mmHg. At least one blood pressure measurement should be in the above range (based on up to three measurements, 1 minute apart, taken after resting in the supine position for at least 5 minutes);
9. Patients diagnosed with malignancy within the last 5 years, with the exception of treated basal cell carcinoma of the skin, curably resected squamous cell carcinoma of the skin, polyps of the colon, or carcinoma in situ of the cervix;
10. Patients with osteoporosis who are known to be at moderate or high risk. Chinese patients are defined according to the Asian Osteoporosis Self-Assessment Tool (OSTA) Index;
11. Patients with known glaucoma, known history of cataract and/or cataract surgery that may interfere with study drug action or release (such as peptic ulcer disease, inflammatory bowel disease, and chronic diarrhea);
12. Patients who are allergic to budesonide or any component of the investigational drug formulation;
13. Patients who have previously had a severe adverse reaction to steroids;
14. Patients with psychotic symptoms;
15. Have received any systemic glucocorticoid therapy within 3 months prior to medication;
16. Received immunosuppressants or biologics within 3 months prior to medication;
17. Patients taking potent inhibitors of the cytochrome P450 3A4 enzyme (CYP3A4);
18. Current or former (within the last 2 years) alcohol or drug abuse;
19. Patients who are unwilling or unable to meet program requirements;
20. Life expectancy <5 years;
21. Women who are pregnant, nursing, or unwilling to use contraception during treatment.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Treat	TARPEYO 4 MG Delayed Release Oral Capsule	TRF-budesonide enteric-coated capsule（TARPEYO）
Control	RAS inhibitor	RAS blocker

Primary Outcome Measures

Name	Time	Method
Change in Urinary Protein Levels from Baseline at 9 months Primary endpoint	9 months	Assessment of the change in 24-hour urine protein levels from baseline after 9 months of follow-up.
Change in eGFR from Baseline at 9 Months	9 months	Measurement of the change in estimated glomerular filtration rate (eGFR) from baseline after 9 months of follow-up.

Secondary Outcome Measures

Name	Time	Method
Change in 24-Hour Urine Protein Levels Compared to Baseline at 12 Months	12 months	Assessment of the change in 24-hour urine protein levels from baseline after 12 months of follow-up.
Change in eGFR Compared to Baseline at 12 Months	12 months	Measurement of the change in estimated glomerular filtration rate (eGFR) from baseline after 12 months of follow-up.
Incidence Rate of Adverse Events	12 months	Calculation of the incidence rate of adverse events during the study period.

Trial Locations

Locations (1)

Ruijin hospital; 🇨🇳 Shanghai, China